$1.17
+0.09 (+8.33%)
Open$1.17
Previous Close$1.08
Day High$1.19
Day Low$0.97
52W High$27.52
52W Low$11.92
Volume—
Avg Volume786.8K
Market Cap13.73M
P/E Ratio42.18
EPS$0.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,977.8% upside
Current
$1.17
$1.17
Target
$24.31
$24.31
$15.00
$24.31 avg
$29.94
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.99M | 1.82M | 1.81M |
| Net Income | -271,887 | -219,394 | -295,477 |
| Profit Margin | -13.7% | -12.0% | -16.3% |
| EBITDA | -443,981 | -374,843 | -381,153 |
| Free Cash Flow | -242,138 | -341,295 | -221,285 |
| Rev Growth | +6.4% | +1.5% | -4.5% |
| Debt/Equity | 0.27 | 0.23 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |